Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The AACE/ACE Comprehensive Clinical Practice Guidelines also recommend GLP-1 receptor agonists as first-line pharmacotherapy for patients with obesity and type 2 diabetes, given their combined glycemic and weight-reduction profiles [19]
In all three studies, adults with obesity or overweight with at least one weight-related comorbidity were randomly assigned to once-weekly subcutaneous tirzepatide or placebo for 72 weeks
The ATTAIN-MAINTAIN trial demonstrated that patients switching from tirzepatide to orforglipron maintained most of their weight loss, with modest regain of approximately 5 kg on average
doi:10.1016/j.ejim.2017.04.018
studies have shown a 0.6% A1C decrease after approximately 6 months of sitagliptin or alogliptin therapy, compared with 0.5% for saxagliptin and 0.4% for linagliptin
There are companies that are making a lot of revenue by prescribing compounded versions of GLP-1s, and they might try to find some way to continue to do that, agrees Wood
